Expert Point of View: Clifford Hudis, MD


Get Permission

Formal discussant Clifford Hudis, MD, ASCO President and Chief of the Breast Cancer Service at Memorial Sloan-Kettering Cancer Center in New York, commented that the findings were not surprising. “The results of TH3RESA nicely reflect the EMILIA trial and are consistent with those of anti-HER2 therapies. These antibody-based therapies have revolutionized the treatment of a subset of breast cancer patients.”

He said that ado-trastuzumab emtansine should be considered in HER2-positive disease as second-, third- or fourth-line treatment.

Remaining issues are the optimal sequencing of HER2-directed therapies and the best role for ado-trastuzumab emtansine, he added. He also said that there might be biomarkers (not yet identified) for subsets of patients with a preferential response to ado-trastuzumab emtansine. ■

Disclosure: Dr. Hudis reported no potential conflicts of interest.


Related Articles

Strong Showing for Ado-Trastuzumab Emtansine in Advanced HER2-Positive Heavily Pretreated Breast Cancer

Results of the phase III TH3RESA trial show that the antibody-conjugate ado-trastuzumab emtansine (Kadcyla), formerly known as T-DM1, extends progression-free survival in women with advanced HER2-positive breast cancer that progressed on two or more previous HER2-directed therapies including...

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.